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EUROCAT, founded in 1979 as the European Concerted Action on Congenital Anomalies and Twins, is 
a high quality network of population based congenital anomaly registries across Europe for the 
monitoring, surveillance and research of congenital anomalies1. Since its conception the European 
Commission (EC) has funded the EUROCAT Central Registry. 
The EUROCAT Central Registry was based in Brussels from 1979 to 1999 and then moved to the UK. 
From 2000 to 2014 it was accommodated at the University of Ulster, led superbly by Professor Helen 
Dolk. In January 2015 the Central Registry transferred to the European Commission’s Joint Research 
Centre (DG JRC) in Ispra, Italy. EUROCAT is now an integral part of the European Platform on Rare 
Diseases Registration being developed at the JRC2 in close collaboration with the EC’s Directorate for 
Health and Food safety (DG SANTE). 
Over the last two decades EUROCAT has grown, developed and matured in many directions to be 
the successful network that is recognised around the world today. (Other research groups now apply 
our methodology and use our publications as reference). Greater standardisation of definitions, 
diagnoses and terminology were achieved, principally by the development of the EUROCAT guides 
(currently version 1.4)3, the EUROCAT Central Database and the EUROCAT Data Management 
Program (ECD and EDMP) 4 which constrained registers to adopt common practices in data reporting. 
The EUROCAT Coding and Classification Committee from 2003 onwards also played its role, by 
defining cases, developing and disseminating rules around classification and coding and providing 
support and training in applying these rules.  
Currently, the EUROCAT Central Registry holds details on approximately 750,000 cases of congenital 
anomalies collected over the years by 51 registries, contributing either anonymous individual case 
specific data (full members) or  aggregate prevalence data in tables (associate members), from 23 
countries covering almost 30% of European births (1.7 million) per year. 
The great value of EUROCAT is that the data are collected, coded and stored by local registries in a 
standardised way. This inherent homogeneity in the data across Europe5 overcomes the weaknesses 
of many studies which attempt to derive information from heterogeneous datasets. 
One key function of EUROCAT is to publish statistics on outcomes and prevalence rates for a wide 
range of major congenital anomalies annually. The data covers all pregnancy outcomes (including 
terminations) from 20 weeks gestation. Much of this information is freely available on the EUROCAT 
website.6 Having good quality baseline background data is vital when considering possible 
environmental impacts 7. A recent publication highlighted the differences in the diagnosis of 
microcephaly across Europe, a matter of importance when interpreting the prevalence of 
microcephaly across South America with the emergence of Zika virus8. The value of robust baseline 
data has also been demonstrated by work undertaken in Italy9, investigating environmental 
exposures.  
EDMP has a built-in module for calculating trends and clusters, designed as an “early response” 
system10, 11. This can be used by individual registers to review their own data or by the Central 
Registry combining data. It is interesting to see that what can often appear to be a local or national 
trend to an individual register or group of registers within one country can in fact be part of 
something wider and larger across the whole of Europe. Trends may increase because of better 
diagnosis (improvements in antenatal ultrasound scanning for example) or because of 
environmental factors that are not well understood12. For instance there is marked variation in the 
prevalence of gastroschisis in some northern European countries compared to the Mediterranean 
region.13 On the other hand the increasing use of ultrasound scans pre and postnatally has made it 
more difficult to determine and harmonise the exact limit between normal and abnormal findings in 
fetuses and newborn babies.14  
However, perhaps the greatest value of combining data can be seen for rare diseases. No individual 
registry will ever have enough cases to accurately determine prevalence for rare and very rare 
conditions. By combining data this can be achieved. Over recent years, EUROCAT papers have been 
published on Holt-Oram syndrome15, Meckle-Gruber syndrome16, Ocular-Auricular-Vertebral 
syndrome17 and Fraser syndrome18. The value of combining data can be seen even in common 
conditions such as trisomy 21, where factors such as twinning19 require Europe-wide data in order to 
be explored effectively. EUROCAT representatives are also involved with some of the recently 
established European Reference Networks (ERNS) 20 for rare diseases. 
Another area of interest is the impact of health service policies and practice. Improvements in 
antenatal detections of anomalies and increasing survival for live born infants seen with cardiac 
anomalies demonstrate this21.  Other work includes the development of indicators to summarise the 
public health impact of congenital anomalies, including mortality. Survival to 1 week and 1 year 
varies enormously between countries mainly because of different legislation regarding termination. 
Death at 1 week is much higher in those countries where terminations are not legal (Malta and 
Ireland) compared to other countries.22, 23 
The lack of fortification of foodstuffs with folic acid in European countries has been a matter of deep 
regret to EUROCAT. Whilst the United States24, Canada25 and other places26, 27 have been able to 
demonstrate a significant fall in the rates of neural tube defects due to fortification, EUROCAT 
consistently reports that neural defects rates across Europe remain stubbornly stable. Sadly this 
demonstrates usefulness in highlighting a failure of Public Health action in the European member 
states.28, 29, 30 
EUROCAT continues to develop methods to improve the surveillance of congenital anomalies. One 
example is the development of a coding algorithm, which has been implemented in EDMP to allow 
for classification of multiple congenital anomalies where there is no unifying diagnosis of a syndrome 
or chromosomal anomaly for separate surveillance. Patterns of occurrence are looked for, which 
may suggest possible pathways for teratogens, or other aetiological causation31.  
Pharmocovigilance has been an area of study of increasing importance over the last 10 years.32, 33 
EUROCAT has demonstrated the value of such work, particularly through the EUROmediCAT 
project34 in which medications taken during the first trimester of pregnancy, for certain long-term or 
chronic diseases have been assessed. The medications studied include anti-epileptics, SSRIs, anti-
asthmatics, and diabetic medicines.  The EUROmediCAT project involved a data-linkage approach 
between registers and national prescription databases. 
Recently a new data-linkage project has been launched – EUROlinkCAT35 funded by the Horizon 2020 
project. By linking data between registers and other national databases, it is hoped that a far more 
detailed and extensive picture can be described on the long-term consequence for infants born with 
major congenital anomalies; consequences in terms of survival, morbidity, health service usage and 
demands, and educational achievement. 
These linkage projects highlight a widespread change in registration practice in recent years, with 
less reliance upon paper reports and linkage to health databases and systems becoming routine at 
the local level. 
Collaborative studies are often developed by thematic Working Groups that are constituted 
whenever new research needs arise. Two recently established groups are Genetics, and Health 
Inequalities. In this way EUROCAT remains relevant and flexible to adapt to changes in the clinical 
world. 
EUROCAT is an invaluable resource. With so many opportunities for further studies, and for pushing 
forward the scientific understanding of congenital anomalies, a bright future for EUROCAT beckons. 
We are confident that being part of the European Platform on Rare Disease Registration will give the 
stability and support to build upon EUROCAT’s past successes and to achieve even greater things in 
the years ahead. 
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